3.27
price up icon0.31%   0.01
after-market Dopo l'orario di chiusura: 3.30 0.03 +0.92%
loading
Precedente Chiudi:
$3.26
Aprire:
$3.32
Volume 24 ore:
7,244
Relative Volume:
0.15
Capitalizzazione di mercato:
$17.50M
Reddito:
-
Utile/perdita netta:
$-16.35M
Rapporto P/E:
-1.0721
EPS:
-3.05
Flusso di cassa netto:
$-11.88M
1 W Prestazione:
+3.15%
1M Prestazione:
+4.14%
6M Prestazione:
-27.97%
1 anno Prestazione:
-48.99%
Intervallo 1D:
Value
$3.27
$3.32
Intervallo di 1 settimana:
Value
$3.10
$3.32
Portata 52W:
Value
$2.6838
$6.50

Lipocine Inc Stock (LPCN) Company Profile

Name
Nome
Lipocine Inc
Name
Telefono
801 994 7383
Name
Indirizzo
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Name
Dipendente
16
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
LPCN's Discussions on Twitter

Confronta LPCN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LPCN
Lipocine Inc
3.27 17.44M 0 -16.35M -11.88M -3.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Lipocine Inc Stock (LPCN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-06-24 Iniziato Cantor Fitzgerald Overweight
2020-12-10 Aggiornamento Ladenburg Thalmann Neutral → Buy
2018-01-12 Reiterato H.C. Wainwright Buy
2018-01-11 Downgrade Canaccord Genuity Buy → Hold
2017-12-08 Ripresa H.C. Wainwright Buy
2016-10-07 Iniziato H.C. Wainwright Buy
2015-07-22 Iniziato ROTH Capital Buy
2015-06-23 Iniziato Canaccord Genuity Buy
Mostra tutto

Lipocine Inc Borsa (LPCN) Ultime notizie

pulisher
Jul 23, 2025

Is Lipocine Inc. a good long term investmentFree Wealth Planning Blueprint - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Lipocine Inc. stockFree Daily Trading Room Entry - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Lipocine Inc. stock priceBreakthrough stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lipocine Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 16, 2025

What makes Lipocine Inc. stock price move sharplyTrade With Low Risk Exposure - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

How Lipocine Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Lipocine Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential - Investing.com Australia

Jul 11, 2025
pulisher
Jun 30, 2025

Lipocine stock maintains Buy rating at H.C. Wainwright as Phase 3 trial begins - Investing.com

Jun 30, 2025
pulisher
Jun 27, 2025

First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online

Jun 27, 2025
pulisher
Jun 26, 2025

LPCN Begins Pivotal Phase 3 Trial for Postpartum Depression Treatment | LPCN Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Lipocine Begins Phase 3 Trial for LPCN 1154 - TipRanks

Jun 26, 2025
pulisher
Jun 23, 2025

Lipocine to Host R&D Event on July 9 - TipRanks

Jun 23, 2025
pulisher
Jun 23, 2025

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - Yahoo Finance

Jun 23, 2025
pulisher
Jun 12, 2025

HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PR Newswire

Jun 09, 2025
pulisher
Jun 09, 2025

Lipocine’s Partner Files New Drug Submission in Canada - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow

Jun 09, 2025
pulisher
Jun 09, 2025

Groundbreaking Oral Testosterone Treatment Eyes 700,000-Strong Canadian Market After FDA Success - Stock Titan

Jun 09, 2025
pulisher
Jun 06, 2025

Lipocine Inc. (NASDAQ:LPCN) Short Interest Update - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Lipocine Approves Key Proposals at Shareholder Meeting - TipRanks

Jun 04, 2025

Lipocine Inc Azioni (LPCN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):